EVEduardo Vilar

Eduardo Vilar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eduardo Vilar has a total of 954 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table S1 from The Immunological Landscape of Colorectal Precancers: A Systematic Review

    by Gabriel A. del Carmen, Gregory Deeb, Nan Deng, Krishna M. Sinha, Marco Matejcic, Eduardo Vilar, Stephanie L. Schmit

    Supplementary Table S1 presents the complete PRISMA 2020 checklist, indicating where each reporting item appears in the manuscript.

  • Open Access

    Data from The Immunological Landscape of Colorectal Precancers: A Systematic Review

    by Gabriel A. del Carmen, Gregory Deeb, Nan Deng, Krishna M. Sinha, Marco Matejcic, Eduardo Vilar, Stephanie L. Schmit

    Colorectal cancer develops predominantly through the adenoma-to-carcinoma sequence, with immunologic processes playing a central yet incompletely understood role in this progression. A systematic review was conducted of published academic literature using the MEDLINE, Embase, and Cochrane Library databases to identify studies that examined immune cell infiltration, cytokine profiling, and immune surveillance in colorectal precancers. Studies published between October 1974 and July 2021 were included. Adaptive immune cells demonstrate dynamic infiltration patterns at various points along the adenoma–carcinoma sequence, with certain subsets of these lymphocytes facilitating tumor progression through immunosuppression, whereas others confer protection. In contrast, innate immune cells demonstrate context-dependent roles in which precancers may or may not develop into malignancies. Cytokine networks, particularly interleukin-6 (IL-6), IL-8, and IL-17, further modulate the tumor microenvironment. The immunologic landscape of colorectal precancers is complex, bidirectional, and nonlinear in its relationships. Understanding these mechanisms provides a foundation for the development of immunologically informed prevention and early detection and intervention to mitigate the colorectal cancer burden.

  • Open Access

    Supplementary Table S2 from The Immunological Landscape of Colorectal Precancers: A Systematic Review

    by Gabriel A. del Carmen, Gregory Deeb, Nan Deng, Krishna M. Sinha, Marco Matejcic, Eduardo Vilar, Stephanie L. Schmit

    Supplementary Table S2 lists all 171 included studies by colorectal pre-cancer pathway, ordered by first author, with study population, assay, and immune findings.

  • Open Access

    Supplementary Table S3 from The Immunological Landscape of Colorectal Precancers: A Systematic Review

    by Gabriel A. del Carmen, Gregory Deeb, Nan Deng, Krishna M. Sinha, Marco Matejcic, Eduardo Vilar, Stephanie L. Schmit

    Supplementary Table S3 summarizes the immune components reported in each pre-cancer pathway and their role in colorectal tumorigenesis across the included studies.

  • Duodenal involvement in MUTYH-associated polyposis: findings from an international study and implications for endoscopic surveillance.

    by Becky Truscott, Imogen Bennett, Arron S. Lacey, Arthur S. Aelvoet, Angel Alonso Sanchez, M. Rosario Aznárez, Ann-Sofie Backman, Jan Bjork, Gabriel Capella, Susan K. Clark, et al.

    Objectives: This study aimed to better document incidence and progression of duodenal disease in MUTYH -associated polyposis (MAP). Methods: Incidences of duodenal cancer, and duodenal polyposis by age and genotype were assessed in individuals with genetically confirmed MAP. Results: At first endoscopy, 91/679 participants (13.4%) had duodenal adenoma(s) at a median age of 53 years (range 22 to 81 years). 439/679 participants had 1370 further endoscopies, over a median period of 6.3 years (range 1 month to 30 years). This included 365 without adenomas at first endoscopy, of whom 83 (22.7%) developed non-ampullary adenomas during follow-up at a median age of 53 years (range 29-76). Thirty-eight adenomas (5.5%) contained high-grade dysplasia (HGD), of which thirty-five had a known size and 20 (57.1%) of these were 10mm or smaller. Ampullary lesions were uncommon (31/679, 4.6%). Duodenal cancer was diagnosed in 5/679 participants (0.74%) at a median age of 65 years (range 47-83 years) and at a median of 12 months (range 9-24 months) following a surveillance endoscopy. At least four were located distally (in the third or fourth part). The cumulative incidences of duodenal adenomas and cancer at 70 years were 16.5-63.5%, depending on genotype, and 0.58%, respectively. Adenoma incidence was significantly higher in Y179C (hazard ratio 5.33 (2.94–9.67, <0.001) and E480X (4.07 (2.16–7.67), <0.001) than G396D homozygotes. Conclusions: Future clinical guidelines for MAP should consider genotype-specific recommendations for duodenal surveillance, the importance of assessing the distal duodenum (i.e. D3, D4) and polypectomy of all detectable adenomas.

  • Open Access

    Characterization of circulating neoantigen-specific T cell responses and public T cell receptors shaping immune memory in Lynch syndrome carriers

    by Fahriye Duzagac, Nan Deng, Jinling Wang, Supriya Nagaraju, Peter Steinberger, Alexandre Reuben, Krishna M. Sinha, Eduardo Vilar

  • The Immunological Landscape of Colorectal Precancers: A Systematic Review

    by Gabriel A. del Carmen, Gregory Deeb, Nan Deng, Krishna M. Sinha, Marco Matejcic, Eduardo Vilar, Stephanie L. Schmit

    Colorectal cancer develops predominantly through the adenoma-to-carcinoma sequence, with immunologic processes playing a central yet incompletely understood role in this progression. A systematic review was conducted of published academic literature using the MEDLINE, Embase, and Cochrane Library databases to identify studies that examined immune cell infiltration, cytokine profiling, and immune surveillance in colorectal precancers. Studies published between October 1974 and July 2021 were included. Adaptive immune cells demonstrate dynamic infiltration patterns at various points along the adenoma–carcinoma sequence, with certain subsets of these lymphocytes facilitating tumor progression through immunosuppression, whereas others confer protection. In contrast, innate immune cells demonstrate context-dependent roles in which precancers may or may not develop into malignancies. Cytokine networks, particularly interleukin-6 (IL-6), IL-8, and IL-17, further modulate the tumor microenvironment. The immunologic landscape of colorectal precancers is complex, bidirectional, and nonlinear in its relationships. Understanding these mechanisms provides a foundation for the development of immunologically informed prevention and early detection and intervention to mitigate the colorectal cancer burden.

  • Open Access

    Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signatures

    by Nan Deng, Fahriye Duzagac, Ana M. Bolivar, Laura Reyes-Uribe, Melissa W. Taggart, Selvi Thirumurthi, Luigi Ricciardiello, Patrick M. Lynch, Y. Nancy You, Scott Kopetz, et al.

    Lynch Syndrome (LS) provides the perfect context to understand DNA mismatch repair deficient carcinogenesis, which is characterized by neoplastic lesions with high rates of shared neoantigens eliciting adaptive immunity through T cell receptor (TCR) recognition. However, the TCR landscape in LS carriers remains unexplored. Here, we perform TCR sequencing of 277 blood samples from LS cancer survivors, previvors, and controls, as well as matching colorectal cancers and pre-cancers. We show that up to 41% of the most expanded TCRβs from colorectal neoplasms are detectable in the blood of LS carriers, while showing minimal expansion in controls. In addition, we develop and validate a classification model that distinguishes LS carriers from controls using circulating TCRβs signatures associated with LS independent of thecancer history and with cancer-free LS previvors. Together, our findings characterize circulating and tissue TCRβs associated with LS, thus representing a step toward identifying blood-based TCR biomarkers for immune surveillance.


  • Top Cited Papers
    Open Access

    Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial

    by Anna Morena D’ALise, Jason Willis, Fahriye Duzagac, Michael J. Hall, Marcia Cruz-Correa, Gregory E. Idos, Selvi Thirumurthi, Veroushka Ballester, Guido Leoni, Irene Garzia, et al.

    Cancer interception is a preventative approach aiming to reduce cancer incidence by targeting precancers and early-stage cancers. Lynch syndrome (LS) is a prevalent hereditary cancer syndrome affecting ~1 in 300 individuals, with an overall lifetime cancer risk as high as 80%. LS is caused by germline mutations in the DNA mismatch repair genes, leading to microsatellite instability (MSI) and accumulation of shared mutations. When these occur in coding regions, they generate frameshift peptides (FSPs). Nous-209 is a neoantigen-directed immunotherapy based on a heterologous prime boost using great ape adenovirus and modified vaccinia virus Ankara encoding 209 FSPs shared across MSI neoplasms. We present the results from cohort 1 of a phase 1b/2 single-arm trial of Nous-209 for cancer interception in LS carriers (n = 45). Safety and immunogenicity were coprimary endpoints. Safety was assessed in 45 participants. Vaccination was safe with no intervention-related serious adverse events (AEs). The most common AEs were injection-site reactions (any grade in 91% of participants after prime and 76% after boost with no grade 3) and fatigue (any grade in 80% after prime and 53% after boost with 4% grade 3 after prime or after boost). Neoantigen-specific immune responses were observed after vaccination in 100% of evaluable participants (n = 37), with induction of potent T cell immunity (mean response at peak of ~1,100 interferon-γ spot-forming cells per million peripheral blood mononuclear cells). The immune response was durable and detectable at 1 year in 85% of participants. Both CD8+ and CD4+ T cells were induced, recognizing multiple FSPs. Peptide–human leukocyte antigen predictions allowed the identification of >100 immunogenic FSPs with demonstration of cytotoxic activity in vitro. Immunogenic FSPs were found in independent datasets of LS MSI colorectal precancers and cancers. These results highlight Nous-209 ability to efficiently stimulate immunity against neoantigens in LS, supporting its development for cancer interception (ClinicalTrials.gov identifier: NCT05078866).


  • Open Access

    Supplementary Table 1 from Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis

    by Irene Maria Briata, Stefano Spinaci, Parijatham S. Thomas, Davide Serrano, Tania Buttiron Webber, Nicoletta Gandolfo, Flavio Guasone, Andrea Rattaro, Emma Firpo, Mauro D’aMico, et al.

    Supplementary Table 1: Representativeness of Study Participants